Meghan Harris

Meghan Harris started their work experience in 2003 as a Research Technician at Tufts University School of Medicine, where they assisted in examining the expression of olfactory receptor genes in rodents. In 2007, they worked as an Undergraduate Research Assistant at the Massachusetts Institute of Technology. In 2008, they joined Genzyme Corporation as a Research Assistant, responsible for compound library management and assisting with biochemical kinase assays. From 2011 to 2017, Meghan worked at Sanofi as a Senior Research Associate, where they developed and performed LCMS assays and played a role in medium-throughput screens. Starting from 2017, they became a PHD Candidate and Graduate Student at Brandeis University, where they conducted research and completed their PHD in 2022. Recently, in 2022, they joined Myeloid Therapeutics as a Senior Scientist.

Meghan Harris earned a Bachelor of Science degree in Biology from the Massachusetts Institute of Technology, where they studied from 2004 to 2008. After completing their undergraduate studies, they pursued further education at Brandeis University. From 2017 to 2019, they obtained a Master's degree in Cell/Cellular and Molecular Biology. Following their Master's, Meghan Harris continued their studies at Brandeis University, where they are currently working towards a Doctor of Philosophy (PhD) in Molecular and Cell Biology, a program they enrolled in 2017 and is expected to complete in 2022.